Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
Manali Kamdar(University of Colorado Cancer Center), Scott R. Solomon(Northside Hospital), Jon Arnason(Beth Israel Deaconess Medical Center), Patrick B. Johnston(Mayo Clinic in Arizona), Bertram Glaß(Helios Hospital Berlin-Buch), Veronika Bachanová(University of Minnesota), Sami Ibrahimi(University of Oklahoma), Stephan Mielke(Karolinska Institutet), Pim Mutsaers(Erasmus MC), Francisco J. Hernandez‐Ilizaliturri(Roswell Park Comprehensive Cancer Center), Koji Izutsu(Tokyo National Hospital), Franck Morschhauser(Université de Lille), Matthew A. Lunning(University of Nebraska Medical Center), David G. Maloney(Fred Hutch Cancer Center), Alessandro Crotta(Bristol-Myers Squibb (Switzerland)), Sandrine Montheard(Bristol-Myers Squibb (Switzerland)), Alessandro Previtali(Bristol-Myers Squibb (Switzerland)), Lara Stepan(Bristol-Myers Squibb (United States)), K. OGASAWARA(Bristol-Myers Squibb (United States)), Timothy R. Mack(Bristol-Myers Squibb (United States)), Jeremy S Abramson(Massachusetts General Hospital)
Cited by 741
Abstract
Related Papers
No related papers found
Powered by citation graph analysis